Following a full submission
1 mg estradiol / 2 mg drospirenone (Angeliq) is not recommended for use within NHS Scotland for prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or have contra-indications to, other medicinal products approved for the prevention of osteoporosis.
It maintains bone mineral density, relative to placebo, in post-menopausal women. However, no evidence of cost-effectiveness has been presented.
- Medicine name:
- 1 mg estradiol/2 mg drospirenone (Angeliq®)
- SMC ID:
- Prevention of osteoporosis
- Date advice published:
- 09 January 2006